A patient with hemoglobin A1c of 7.9% is on empagliflozin (Jardiance) 25 mg; what additional medication should be added if she cannot take a GLP‑1 receptor agonist?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Add Metformin as the Next Step

For a patient with A1c 7.9% on Jardiance 25 mg who cannot take GLP-1 receptor agonists, add metformin immediately if not already prescribed, or if already on metformin, add a DPP-4 inhibitor (linagliptin preferred given the existing SGLT2 inhibitor). 1

Rationale and Treatment Algorithm

First: Confirm Metformin Status

The 2025 ADA Standards explicitly recommend metformin as foundational therapy for type 2 diabetes unless contraindicated 1. Since your patient is on Jardiance alone:

  • If NOT on metformin: Add metformin immediately, titrating to 2000 mg daily (or maximum tolerated dose). This combination (SGLT2i + metformin) is FDA-approved and demonstrated A1c reductions of 0.6-0.8% in clinical trials 2.

  • If ALREADY on metformin: Proceed to add a third agent (see below).

Second: If Already on Metformin + Jardiance

With A1c still at 7.9% (0.9% above the typical 7.0% target), you need triple therapy. Since GLP-1 agonists are contraindicated, your best options are:

Primary Recommendation: Add DPP-4 Inhibitor (Linagliptin 5 mg)

  • The combination of empagliflozin + linagliptin + metformin achieved A1c reductions of 1.08-1.24% from baseline in treatment-naive patients 3
  • As add-on to metformin, empagliflozin 25 mg + linagliptin 5 mg reduced A1c by 1.19% versus 0.62% with empagliflozin alone 4
  • 61.8% of patients achieved A1c <7% at 24 weeks with this triple combination 4
  • Excellent safety profile with no hypoglycemia requiring assistance 4, 3
  • Complementary mechanisms: SGLT2i (renal glucose excretion) + DPP-4i (incretin enhancement) + metformin (hepatic glucose production)

Alternative: Add Basal Insulin

  • Consider if A1c remains >1.5% above goal or if symptoms of hyperglycemia exist 1
  • Start with 10 units daily or 0.1-0.2 units/kg
  • Titrate by 2 units every 3 days targeting fasting glucose 80-130 mg/dL
  • Caution: Higher hypoglycemia risk; requires glucose monitoring and patient education

Third-Line Alternative: Add Pioglitazone

  • Empagliflozin 25 mg added to pioglitazone (with or without metformin) reduced A1c by 0.69% versus placebo over 76 weeks 5
  • Major caveats: Weight gain, fluid retention, heart failure risk, bone fracture risk in women, bladder cancer concerns
  • Generally avoided unless specific insulin resistance features present

Key Clinical Considerations

Why Not Sulfonylureas?

While technically an option, sulfonylureas carry significant hypoglycemia risk, promote weight gain, and lack cardiovascular/renal benefits that characterize modern diabetes therapy. The 2025 guidelines de-emphasize their use 1.

Cardiovascular and Renal Context

The 2021 ESC/ADA guidelines prioritize SGLT2 inhibitors (which your patient already has) for cardiovascular and renal protection 6. Since she's already on maximum-dose Jardiance:

  • Ensure she has appropriate cardiovascular risk assessment
  • Monitor for albuminuria and eGFR
  • The SGLT2i provides MACE reduction, heart failure hospitalization reduction, and CKD progression prevention independent of glucose lowering 6

Monitoring Plan

After adding therapy:

  • Recheck A1c in 3 months
  • If A1c remains >7.5% despite triple therapy, consider basal insulin addition
  • Monitor for genital mycotic infections (SGLT2i effect) and gastrointestinal symptoms (metformin/DPP-4i)
  • No increased hypoglycemia risk with this combination 4, 3

Cost and Access Considerations

If cost is prohibitive for DPP-4 inhibitors, metformin intensification (if not at maximum dose) or addition of sulfonylurea becomes pragmatic, though less ideal. Basal insulin (NPH) remains the most cost-effective injectable option if needed 1.

The evidence strongly supports DPP-4 inhibitor addition to your current SGLT2i + metformin regimen, with linagliptin specifically studied in combination with empagliflozin showing superior efficacy and excellent tolerability. 4, 3

Related Questions

In a patient with type 2 diabetes mellitus and a hemoglobin A1c of 8.3% who is taking metformin 1000 mg twice daily, should empagliflozin (Jardiance) be added?
In a type 2 diabetes patient with HbA1c 9.4% on linagliptin (Tradjenta) 5 mg daily and empagliflozin (Jardiance) 25 mg daily who refuses GLP‑1 receptor agonists and insulin, what is the appropriate next pharmacologic step?
What should be added next to empagliflozin (Jardiance) and metformin in a 74‑year‑old man with type 2 diabetes who declines a GLP‑1 receptor agonist (semaglutide, Ozempic) and has hyperglycemia (elevated fasting glucose and hemoglobin A1c)?
In a patient with type 2 diabetes whose HbA1c increased from 5.8% to 6.3% while on once‑daily Synjardy (empagliflozin 12.5 mg/linagliptin 5 mg), is it appropriate to switch to twice‑daily Synjardy dosing and add Ozempic (semaglutide)?
Can a patient with type 2 diabetes who is already taking long‑acting (basal) insulin and empagliflozin (Jardiance) start a GLP‑1 receptor agonist?
Can albendazole 400 mg be taken twice within one week?
How should I manage akathisia in a female patient taking aripiprazole (Abilify)?
What is the appropriate management for subcutaneous emphysema that develops after removal of a chest tube?
In a patient with sinus bradycardia and prominent U waves on the ECG, what precautions and management should be undertaken?
After taking albendazole 400 mg without chewing, can I safely repeat the dose or take pyrantel pamoate within a two‑day interval, and which medication is recommended for intense itching?
Should a patient with moderate aortic stenosis be referred to cardiology for formal evaluation and ongoing management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.